Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients (OUEST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02893410|
Recruitment Status : Completed
First Posted : September 8, 2016
Last Update Posted : September 21, 2018
|Condition or disease|
|Polycythemia Vera Essential Thrombocythemia|
During one year, all patients with PV or ET followed in our centre, and who took a drug to treat their MPN, were identified.
The investigators submitted by mail or directly at the consultation a unique questionnaire containing 25 questions concerning patients characteristics, evaluation of observance, identification of side effects and own appreciation of the drug.
After completion of the questionnaire, the patients were identified and followed to collect new data about thrombotic events or phenotypic evolution.
|Study Type :||Observational|
|Actual Enrollment :||286 participants|
|Official Title:||Etude de l'Observance thérapeutique et Des Effets Secondaires Des Traitements Chez Les Patients traités Pour Polyglobulie de Vaquez et thrombocytémie Essentielle|
|Actual Study Start Date :||December 2014|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2015|
- Rate of adherence to drug prescription [ Time Frame: At inclusion ]prospective evaluation in a one shot questionnaire given to each treated patient seen at the consultation distributed between december 2014 and december 2015
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02893410
|CHRU de Brest|
|Brest, France, 29609|
|Study Director:||Jean-Christophe Ianotto, MD||CHRU de Brest|